Dextromethorphan and quinidine combination for heroin detoxification

American Journal on Addictions

Volumn 17, Issue 3, 2008, Pages 176-180

  Akerele, Evaristo ^a   Bisaga, Adam ^a   Sullivan, Maria A ^a   Garawi, Fatima ^a   Comer, Sandra D ^a   Thomas, Anil A ^a   Nunes, Edward V ^a   Kleber, Herbert D ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN; DIAMORPHINE; MORPHINE; PLACEBO; QUINIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; RATING SCALE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADULT; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT DROPOUTS; QUINIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 45849139697     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802019543     Document Type: Article

References (24)

1. Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004;5:713-725.
2. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000;59:1-15.
3. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl). 2001;157:1-10.
4. Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol. 1993;238:209-216.
5. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992;7:190-199.
6. Bisaga A, Gianelli P, Popik P. Opiate withdrawal with dextromethorphan. Am J Psychiatry. 1997;154:584.
7. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
8. Akerele EO, Levin F, Nunes E, Brady R, Kleber H. Effects of HIV triple therapy on methadone levels. Am J Addict. 2002;11:308-314.
9. Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg. 1996;84:860-866.
10. Wiley JL, Harvey SA, Balster RL, Nicholson KL. Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology (Berl). 2003;165:378-385.
11. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Detrophan Study Group. Stroke 1995;26:254-258.
12. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004;44:1132-1142.
13. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63:1364-1370.
14. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780-787.
15. Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther. 2006;28:1607-1618.
16. Himmelsbach C. The morphine abstinence syndrome: its nature and treatment. Ann Intern Med. 1941;15:829-839.
17. Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther. 1995;33:13-19.
18. Koyuncuoglu H, Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther. 1990;28:147-152.
19. Farzin D. Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. Eur J Pharmacol. 1999;377:35-42.
20. Koyuncuoglu H, Gungor M, Sagduyu H, Aricioglu F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol Biochem Behav. 1990;35:829-832.
21. Manning BH, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996;67:79-88.
22. Zhu H, Jenab S, Jones KL, Inturrisi CE. The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat. Brain Res Rev. 2003;142:209-213.
23. Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur J Pharmacol. 1996;307:251-257.
24. Kazis A, Kimiskidis V, Niopas I. Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients. Acta Neurol Scand. 1996;93:94-98.